Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014

Details for Mechanism ID: 11708
Country/Region: Botswana
Year: 2014
Main Partner: U.S. Centers for Disease Control and Prevention
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: HHS/CDC
Total Funding: $550,000 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

Tuberculosis (TB) is a leading cause of mortality among HIV infected persons in Botswana. Traditional TB testing (smear microscopy) has poor sensitivity in persons with HIV. Gene Xpert, a new WHO recommended TB diagnostic technology, has increased sensitivity when compared to microscopy, especially among persons with HIV. XPRES (Xpert Package Rollout Evaluation) is an operational research study conducted by CDC Botswana, partnering with the GoB.

The main goal of the XPRES study is to compare sensitivity of the Xpert and microscopy algorithms and their impact on TB disease burden in Botswana. XPRES is taking place in 11 districts with the highest HIV and TB rates in Botswana. Study participants include HIV-positive persons who present at HIV clinics for care and treatment. XPRES has a complete M&E component, involving quarterly lab supervision visits and routine analysis of data exported from the Xpert machine.

Preliminary results from this study, including lessons learned about Xpert placement, operation and M&E, have informed the GoB in their own current efforts with Xpert, and findings of the study will continue to guide the national rollout. At the close of this study, CDC will continue to provide guidance, but the responsibility and funding of this continued effort will be with the GoB; GoB has already started to fund and implement this effort by introducing Xpert at 12 sites over the past 7 months.


Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $450,000
Laboratory Infrastructure (HLAB) $100,000
Testing: HIV Testing and Counseling (HVCT) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

This mechanism has no published performance targets or indicators.